Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study
Open Access
- 2 May 2020
- journal article
- research article
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 19 (1) , 1-9
Abstract
Background: Despite the known association between non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD), whether NAFLD predicts future CVD events, especially CVD mortality, remains uncertain. We evaluated the relationship between fatty liver index (FLI), a validated marker of NAFLD, and risk of major adverse cardiac events (MACEs) in a large population-based study. Methods: We identified 3011,588 subjects in the Korean National Health Insurance System cohort without a history of CVD who underwent health examinations from 2009 to 2011. The primary endpoint was a composite of cardiovascular deaths, non-fatal myocardial infarction (MI), and ischemic stroke. A Cox proportional hazards regression analysis was performed to assess association between the FLI and the primary endpoint. Results: During the median follow-up period of 6 years, there were 46,010 cases of MACEs (7148 cases of cardiovascular death, 16,574 of non-fatal MI, and 22,288 of ischemic stroke). There was a linear association between higher FLI values and higher incidence of the primary endpoint. In the multivariable models adjusted for factors, such as body weight and cholesterol levels, the hazard ratio for the primary endpoint comparing the highest vs. lowest quartiles of the FLI was 1.99 (95% confidence interval [CIs], 1.91–2.07). The corresponding hazard ratios (95% CIs) for cardiovascular death, non-fetal MI, and ischemic stroke were 1.98 (1.9–2.06), 2.16 (2.01–2.31), and 2.01 (1.90–2.13), respectively (p < 0.001). The results were similar when we performed stratified analyses by age, sex, use of dyslipidemia medication, obesity, diabetes, and hypertension. Conclusions: Our findings indicate that the FLI, which is a surrogate marker of NAFLD, has prognostic value for detecting individuals at higher risk for cardiovascular events.Keywords
All Related Versions
Funding Information
- Korea National Research Foundation (NRF-2019R1G1A109408)
This publication has 32 references indexed in Scilit:
- Understanding Bile Acid Signaling in Diabetes: From Pathophysiology to Therapeutic TargetsDiabetes & Metabolism Journal, 2019
- Nonalcoholic Fatty Liver Disease and Diabetes: Part II: TreatmentDiabetes & Metabolism Journal, 2019
- Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and DiagnosisDiabetes & Metabolism Journal, 2019
- The fatty liver index as a predictor of incident chronic kidney disease in a 10-year prospective cohort studyPLOS ONE, 2017
- Fatty liver index as a simple predictor of incident diabetes from the KoGES-ARIRANG studyMedicine, 2016
- Non-alcoholic fatty liver disease and risk of cardiovascular diseaseMetabolism, 2016
- Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groupsDigestive and Liver Disease, 2015
- A Prospective Study of Fatty Liver Index and Incident Hypertension: The KoGES-ARIRANG StudyPLOS ONE, 2015
- Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver diseaseAlimentary Pharmacology & Therapeutics, 2014
- Corrigendum:The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological AssociationAmerican Journal of Gastroenterology, 2012